Nick Dixon-Clegg

CuraGen Corp. develops protein, antibody and small molecule pharmaceutical products. The firm focuses on the development of CR011-vcMMAE, a Phase II clinical trial drug for the treatment of patients with metastatic melanoma and breast cancer. The company was founded in 1991 and is headquartered in Branford, CT.

Anthra Pharmaceuticals, Inc. is an American company.

Bayer Healthcare LLC provides healthcare and pharmaceutical medicines. It also provides researching, developing, manufacturing and marketing services for the prevention, diagnosis and treatment of diseases. The company is headquartered in Whippany, NJ.

Axellis, Inc. sells and distributes medical devices. Its products are used for oncology and cardiology. The company was founded in August 2007 and is headquartered in London, UK

Powderject Pharmaceuticals Plc develops pharmaceutical products. It offers researching, developing, manufacturing and marketing for existing and next generation vaccines. The company was founded in 1993 and is located in Oxford, UK

MediGene, Inc. develops herpes simplex virus technologies for the treatment of tumors and for gene delivery. The company was founded by Ram Bhatt and Frank Tufaro and is headquartered in San Diego, CA.

Oxagen Ltd. develops novel molecule drugs to treat inflammatory and respiratory diseases. It offers OC000459, an oral CRTH2 antagonist for the treatment of eosinophilic asthma and allergic rhino conjunctivitis. The company was founded by Nick Cross, John Irving Bellin, Mark Edwards, Trevor J. Nicholls and Ian Michael Laing on September 05 1996 and is headquartered in London, the United Kingdom.

Part of Commerzbank AG, Commerzbank Finance Ltd. is a British company that provides securities brokerage services. The company is based in London, UK. Commerzbank Finance was founded in 1955.

BioVex Ltd. operates as a biotechnology firm. It focuses on the development and commercialization of biological treatments for cancer and the prevention of infectious disease. The company was founded on December 15, 1997 and is headquartered in Cambridge, the United Kingdom.

Oxfordshire Biotechnet Ltd. is a venture capital fund.

Oxitec Ltd. develops solutions for controlling harmful insect pests. It provides biological and development research services in controlling insects that spread diseases and damage crops. Its products include Diamond back moth, Pink bollworm, Medfl,y Mexfly, and Olive fly. The company was founded by Luke Alphey on August 15, 2002 and is headquartered in Abingdon, the United Kingdom.

Adaptimmune Ltd. develops T cell therapies to treat cancer, human immunodeficiency virus, and infectious diseases. It utilizes the T cell to target and destroy cancerous and infected cells by using affinity T cell receptor proteins as a means of strengthening patient T cell responses. The company was founded by Bent K. Jakobsen, James Julian Noble and Helena Katrina Tayton-Martin in 2008 and is headquartered in Oxford, the United Kingdom.

Northland Capital Partners Ltd. provides investment banking services. The private company is based in London, UK. and has subsidiaries in United Kingdom. The British company was founded in 1991. Robert Alan Johnson has been the CEO of the company since 2010.

OBN (UK) Ltd. is a non-profit organization, which focuses on supporting and bringing together the UK’s life sciences companies, corporate partners and investors. The company is headquartered in Abingdon, the United Kingdom.

Celleron Therapeutics Ltd. is an oncology company based in Oxford, UK. The company has deep relationships with Oxford University and is located on the Oxford Science Park. Celleron is focused on developing new and innovative therapies to treat cancer, with a particular emphasis on clinical development. The British company is developing a novel group of clinical products, supported by predictive companion diagnostics, that act through defined molecular mechanisms to prevent cancer cell growth. Celleron's lead products are in clinical trials, supported by a biomarker platform that allows responsive patients to be identified. The company was founded in 2004 and is led by CEO Nick la Thangue.

Oxford Cancer Biomarkers Ltd. provides cancer treatment services. It offers a suite of drug-specific companion diagnostic kits that allow the biomarker to be directly measured in tumor biopsies or patient DNA and thereby patients that respond favorably to the drug identified. The company was founded by David Kerr and Nick LaThangue in 2012 and is headquartered in Oxford, the United Kingdom.

OxOnc Development LP operates as an oncology development company. It offers a drug development model that is based on the expertise and core competencies to design and execute clinical trials in oncology. The firm's business model is an integration of scientific, clinical, operational and financial resources, and provides a value-add proposition to its co-development partner by providing a profit and loss-sparing mechanism to fund research and development efforts externally. The company was founded in 2012 and is headquartered in George Town, Cayman Islands.

Pneumagen Ltd. is engaged in biotechnology services. The company was founded in 2016 and is headquartered in Fife, the United Kingdom.

Argonaut Therapeutics Ltd. develops novel epigenetic therapies. It targets abnormal arginine methylation in cancer. The company was founded by Nicholas La Thangue and is headquartered in Oxford, the United Kingdom.

Sutura Therapeutics Ltd. is a British biopharmaceutical company that is advancing biomolecular medicine through its Peptigo technology platform. The company is based in Macclesfield, UK. Sutura's team is made up of skilled and passionate professionals who bring a unique perspective to the table. The company was founded in 2020, and Edwin J. Wagena has been the CEO of the company since 2021.

Synox Therapeutics Ltd. a clinical stage biopharmaceutical company. The company is headquartered in Dublin, Ireland.